| 2351- | lamb, | Anti-Warburg effect via generation of ROS and inhibition of PKM2/β-catenin mediates apoptosis of lambertianic acid in prostate cancer cells |
| - | in-vitro, | Pca, | DU145 | - | in-vitro, | Pca, | PC3 |
| 2453- | LE, | The Promoting Role of HK II in Tumor Development and the Research Progress of Its Inhibitors |
| - | Review, | Var, | NA |
| 1040- | LE, | Licorice extract inhibits growth of non-small cell lung cancer by down-regulating CDK4-Cyclin D1 complex and increasing CD8+ T cell infiltration |
| - | in-vivo, | Lung, | H1975 |
| 1266- | LE, | Glycyrrhizin suppresses epithelial-mesenchymal transition by inhibiting high-mobility group box1 via the TGF-β1/Smad2/3 pathway in lung epithelial cells |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | BEAS-2B |
| 1306- | LE, | Modulations of the Bcl-2/Bax family were involved in the chemopreventive effects of licorice root (Glycyrrhiza uralensis Fisch) in MCF-7 human breast cancer cell |
| - | in-vitro, | BC, | MCF-7 |
| - | in-vitro, | BC, | MCF-7 |
| 1787- | LE, | Licorice and cancer |
| - | Review, | Var, | NA |
| 1789- | LEC, | Lecithin Supplements and Breast Cancer Risk |
| - | Analysis, | NA, | NA |
| 1790- | LEC, | DHA, | Dietary Crude Lecithin Increases Systemic Availability of Dietary Docosahexaenoic Acid with Combined Intake in Rats |
| - | in-vivo, | Nor, | NA |
| 1791- | LEC, | Vegetable lecithins: A review of their compositional diversity, impact on lipid metabolism and potential in cardiometabolic disease prevention |
| - | Review, | Nor, | NA |
| 1793- | LEC, | Unmasking Sunflower Lecithin: Does Science Support the Claims? |
| - | Review, | NA, | NA |
| 1794- | LEC, | Effects of abomasal infusion of soybean or sunflower lecithin on nutrient digestibility and milk production in lactating dairy cows |
| - | in-vivo, | NA, | NA |
| 1795- | LEC, | Chit, | Self-assembled lecithin-chitosan nanoparticles improve the oral bioavailability and alter the pharmacokinetics of raloxifene |
| - | in-vivo, | Nor, | NA |
| 1796- | LEC, | A comprehensive review on pleiotropic effects and therapeutic potential of soy lecithin |
| - | Review, | NA, | NA |
| 3706- | LEC, | Lecithin for dementia and cognitive impairment |
| - | Review, | AD, | NA |
| 4233- | LEC, | Lecithinized brain-derived neurotrophic factor promotes the differentiation of embryonic stem cells in vitro and in vivo |
| - | in-vitro, | Nor, | NA |
| 1122- | LF, | MTX, | Lactoferrin Reverses Methotrexate Driven Epithelial Barrier Defect by Inhibiting TGF-β Mediated Epithelial to Mesenchymal Transition |
| - | in-vivo, | Colon, | Caco-2 |
| 1064- | LT, | Cisplatin, | Inhibition of cell survival, invasion, tumor growth and histone deacetylase activity by the dietary flavonoid luteolin in human epithelioid cancer cells |
| - | vitro+vivo, | Lung, | LNM35 | - | in-vitro, | CRC, | HT-29 | - | in-vitro, | Liver, | HepG2 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| 1025- | LT, | Api, | Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer |
| - | in-vivo, | Lung, | NA |
| 1125- | LT, | Luteolin suppresses epithelial-mesenchymal transition and migration of triple-negative breast cancer cells by inhibiting YAP/TAZ activity |
| - | in-vitro, | BC, | NA |
| 1060- | LT, | BTZ, | Luteolin inhibits the TGF-β signaling pathway to overcome bortezomib resistance in multiple myeloma |
| - | vitro+vivo, | Melanoma, | NA |
| 1084- | LT, | CHr, | Luteolin and chrysin differentially inhibit cyclooxygenase-2 expression and scavenge reactive oxygen species but similarly inhibit prostaglandin-E2 formation in RAW 264.7 cells |
| - | in-vitro, | Nor, | RAW264.7 |
| 1100- | LT, | Luteolin, a flavonoid, as an anticancer agent: A review |
| - | Review, | NA, | NA |
| 986- | LT, | doxoR, | Luteolin as a glycolysis inhibitor offers superior efficacy and lesser toxicity of doxorubicin in breast cancer cells |
| - | in-vitro, | BC, | 4T1 | - | in-vitro, | BC, | MCF-7 |
| 982- | LT, | Inhibitory effect of luteolin on estrogen biosynthesis in human ovarian granulosa cells by suppression of aromatase (CYP19) |
| - | in-vitro, | Ovarian, | KGN |
| 973- | LT, | Luteolin impairs hypoxia adaptation and progression in human breast and colon cancer cells |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | BC, | MDA-MB-231 |
| 979- | LT, | Luteolin Regulation of Estrogen Signaling and Cell Cycle Pathway Genes in MCF-7 Human Breast Cancer Cells |
| - | in-vitro, | BC, | MCF-7 |
| 4339- | LT, | Luteolin inhibits GPVI-mediated platelet activation, oxidative stress, and thrombosis |
| - | in-vivo, | NA, | NA |
| 4338- | LT, | Luteolin: a natural product with multiple mechanisms for atherosclerosis |
| - | Review, | NA, | NA |
| 4295- | LT, | Luteolin Reduces Alzheimer’s Disease Pathologies Induced by Traumatic Brain Injury |
| - | in-vivo, | AD, | NA |
| 4294- | LT, | Luteolin reduces zinc-induced tau phosphorylation at Ser262/356 in an ROS-dependent manner in SH-SY5Y cells |
| - | in-vitro, | NA, | SH-SY5Y |
| 4293- | LT, | Regulatory Role of NF-κB on HDAC2 and Tau Hyperphosphorylation in Diabetic Encephalopathy and the Therapeutic Potential of Luteolin |
| - | in-vivo, | Diabetic, | NA |
| 4292- | LT, | Luteolin for neurodegenerative diseases: a review |
| - | Review, | AD, | NA | - | Review, | Park, | NA | - | Review, | MS, | NA | - | Review, | Stroke, | NA |
| 4687- | LT, | QC, | Dietary Flavonoids Luteolin and Quercetin Suppressed Cancer Stem Cell Properties and Metastatic Potential of Isolated Prostate Cancer Cells |
| - | in-vitro, | Pca, | DU145 |
| 4883- | LT, | CHr, | BRU, | VitC, | An update of Nrf2 activators and inhibitors in cancer prevention/promotion |
| - | Review, | Var, | NA |
| 1317- | LT, | Luteolin Suppresses Teratoma Cell Growth and Induces Cell Apoptosis via Inhibiting Bcl-2 |
| - | vitro+vivo, | Ovarian, | PA1 |
| 1200- | LT, | Inhibition of Fatty Acid Synthase by Luteolin Post-Transcriptionally Downregulates c-Met Expression Independent of Proteosomal/Lysosomal Degradation |
| - | in-vitro, | Pca, | DU145 |
| 1275- | LT, | Mechanism of luteolin induces ferroptosis in nasopharyngeal carcinoma cells |
| - | in-vitro, | Laryn, | NA |
| 1171- | LT, | The inhibition of β-catenin activity by luteolin isolated from Paulownia flowers leads to growth arrest and apoptosis in cholangiocarcinoma |
| - | in-vitro, | CCA, | NA |
| - | in-vitro, | Nor, | MCF10 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MDA-MB-468 | - | in-vitro, | PC, | Bxpc-3 |
| 2587- | LT, | Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs |
| - | in-vitro, | Lung, | A549 |
| 2588- | LT, | Chemo, | Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell lines to chemotherapeutic drugs via inhibition of the Nrf2 pathway |
| - | in-vitro, | CRC, | HCT116 |
| 2589- | LT, | Chemo, | Luteolin Inhibits Breast Cancer Stemness and Enhances Chemosensitivity through the Nrf2-Mediated Pathway |
| - | in-vitro, | BC, | MDA-MB-231 |
| 2925- | LT, | Luteolin Induces Carcinoma Cell Apoptosis through Binding Hsp90 to Suppress Constitutive Activation of STAT3 |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Nor, | HEK293 | - | in-vitro, | BC, | MCF-7 |
| 2930- | LT, | Luteolin confers renoprotection against ischemia–reperfusion injury via involving Nrf2 pathway and regulating miR320 |
| - | in-vitro, | Nor, | NA |
| 2929- | LT, | Loss of BRCA1 in the cells of origin of ovarian cancer induces glycolysis: A window of opportunity for ovarian cancer chemoprevention |
| - | in-vitro, | Ovarian, | NA |
| 2928- | LT, | Luteolin-mediated increase in miR-26a inhibits prostate cancer cell growth and induces cell cycle arrest targeting EZH2 |
| 2927- | LT, | Luteolin Causes 5′CpG Demethylation of the Promoters of TSGs and Modulates the Aberrant Histone Modifications, Restoring the Expression of TSGs in Human Cancer Cells |
| - | in-vitro, | Cerv, | HeLa |
| 2926- | LT, | Luteolin ameliorates rat myocardial ischemia-reperfusion injury through peroxiredoxin II activation: LUT's cardioprotection through PRX II |
| - | in-vitro, | Nor, | H9c2 |
| 2924- | LT, | Luteolin selectively kills STAT3 highly activated gastric cancer cells through enhancing the binding of STAT3 to SHP-1 |
| - | in-vitro, | GC, | NA | - | in-vivo, | NA, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid